Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

HilleVax, Inc. - Common Stock (NQ: HLVX )

14.16 +0.79 (+5.91%)
Streaming Delayed Price Updated: 1:28 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HilleVax, Inc. - Common Stock

< Previous 1 2 Next >
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
HLVX Stock Earnings: HilleVax Beats EPS for Q4 2023
HLVX stock results show that HilleVax beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Recap: HilleVax Q4 Earnings
Via Benzinga
HilleVax: Q1 Earnings Insights
Via Benzinga
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
HLVX Stock Earnings: HilleVax Misses EPS for Q1 2024
HLVX stock results show that HilleVax missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
From HilleVax, Inc.
Via GlobeNewswire
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will... 
Via Talk Markets
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
Collaboration leverages HilleVax’s leading norovirus vaccine development expertise and adds a Phase 1-ready next-generation program to HilleVax’s pipeline 
From HilleVax, Inc.
Via GlobeNewswire
HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax to Present at Upcoming Investor Conferences
From HilleVax, Inc.
Via GlobeNewswire
HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From HilleVax, Inc.
Via GlobeNewswire
Why HilleVax Shares Are Trading Lower
HilleVax Inc (NASDAQ: HLVX) shares are trading lower by 8.5% to $13.20 Wednesday morning after the company announced pricing of its previously-announced public offering of comm 
Via Benzinga
HilleVax Announces Pricing of Public Offering of Common Stock
From HilleVax, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
HilleVax Announces Proposed Public Offering of Common Stock
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Executive Management Appointments and Promotions
From HilleVax, Inc.
Via GlobeNewswire
HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
From HilleVax, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.